$323 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 82 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics Inccall | $6,755,018 | +28.2% | 651,400 | 0.0% | 2.09% | -3.9% | |
| PHAT | Phathom Pharmaceuticals Incequities | $2,864,000 | +100.6% | 200,000 | 0.0% | 0.89% | +50.4% | |
| TRVI | Trevi Therapeutics Incequities | $2,117,358 | +29.2% | 885,924 | 0.0% | 0.66% | -3.2% | |
| Jasper Therapeutics Incequities | $685,000 | -24.3% | 500,000 | 0.0% | 0.21% | -43.3% | ||
| ALGS | Aligos Therapeutics Incequities | $613,562 | +11.1% | 631,887 | 0.0% | 0.19% | -16.7% | |
| CGEN | Compugen Ltdequities | $376,414 | +62.4% | 330,188 | 0.0% | 0.12% | +20.8% | |
| GLUE | Monte Rosa Therapeutics Incequities | $213,419 | -12.1% | 31,156 | 0.0% | 0.07% | -34.0% | |
| Eloxx Pharmaceuticals Incequities | $210,352 | +55.0% | 54,075 | 0.0% | 0.06% | +16.1% | ||
| Rocket Pharmaceuticals Incwarrants | $19,917 | +72.7% | 104,828 | 0.0% | 0.01% | +20.0% | ||
| Fresh Tracks Therapeutics Incequities | $7,013 | +6.3% | 10,000 | 0.0% | 0.00% | -33.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SilverArc Capital, LLC #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.